Prosecution Insights
Last updated: May 29, 2026

Dyne Therapeutics Inc.

7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
3
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
3
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (3)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (14%)
6
Unknown (86%)

Rejection Statute Mix

BucketCases
§112 only1 (14%)
No statute on record6 (86%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
YAO, LEI 2 60.0% +65.6%
HUYNH, PHUONG N 1 65.7% +53.3%
ROSSI, JULIA ANNE LORRAIN 1 46.4% +60.0%
BERHANE, SELAM 1 61.3% +55.5%
NOAKES, SUZANNE MARIE 1 73.1% +18.3%
HADDAD, MAHER M 1 50.4% +54.3%

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
17796418 ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF BERHANE, SELAM 146d overdue
17791681 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY HADDAD, MAHER M 133d overdue
17791667 MUSCLE-TARGETING COMPLEXES AND USES THEREOF NOAKES, SUZANNE MARIE 128d overdue
17791697 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY YAO, LEI 30d overdue
18017173 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY YAO, LEI 9d
18017179 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES ROSSI, JULIA ANNE LORRAIN 22d
18024486 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES HUYNH, PHUONG N 29d

Top Art Units

Art UnitApps
1641 2
1642 2
1615 1
1675 1
1656 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18024486 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES HUYNH, PHUONG N 1641 Other Non-Final OA 29d Pending Mar 02, 2023
18017179 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES ROSSI, JULIA ANNE LORRAIN 1615 §112 Final Rejection 22d Pending Jan 20, 2023
18017173 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY YAO, LEI 1642 Other Non-Final OA 9d Pending Jan 20, 2023
17796418 ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF BERHANE, SELAM 1675 Other Non-Final OA 146d overdue Pending Jul 29, 2022
17791667 MUSCLE-TARGETING COMPLEXES AND USES THEREOF NOAKES, SUZANNE MARIE 1656 Other Final Rejection 128d overdue Pending Jul 08, 2022
17791681 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY HADDAD, MAHER M 1641 Other Final Rejection 133d overdue Pending Jul 08, 2022
17791697 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY YAO, LEI 1642 Other Final Rejection 30d overdue Pending Jul 08, 2022

Managing Dyne Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month